ATP6v1c1's levels of overexpression and frequency of dysregulation are reminiscent of better known mutations, such as those in the MAPK pathway or p53, which encouraged us to examine its effects in vitro and in mouse models of breast cancer (Figure 1). This evidence concerns the gene TP53 and breast carcinoma.